Starsource Multitrade Ltd vs Welcure Drugs Pharmaceuticals Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Oct 26, 2026

Key Highlights

The Latest Trading Price of Starsource Multitrade Ltd is ₹ 109.99 as of 26 Oct 15:30 . The P/E Ratio of Starsource Multitrade Ltd changed from 10.7 on March 2021 to 0 on March 2026 . This represents a CAGR of -100.00% over 6 yearsThe P/E Ratio of Welcure Drugs & Pharmaceuticals Ltd changed from 37.6 on March 2021 to 0 on March 2026 . This represents a CAGR of -100.00% over 6 years The Market Cap of Starsource Multitrade Ltd changed from ₹ 2.68 crore on March 2021 to ₹ 16.68 crore on March 2026 . This represents a CAGR of 35.63% over 6 yearsThe Market Cap of Welcure Drugs & Pharmaceuticals Ltd changed from ₹ 2.54 crore on March 2021 to ₹ 0 crore on March 2026 . This represents a CAGR of -100.00% over 6 years The revenue of Starsource Multitrade Ltd for the Jun '26 is ₹ 0.07 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the growth of 9.2233718E16% The revenue of Welcure Drugs & Pharmaceuticals Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 revenue of ₹ 0 crore. This represent the decline of 0% The ebitda of Starsource Multitrade Ltd for the Jun '26 is ₹ 0.02 crore as compare to the Mar '26 ebitda of ₹ -0.07 crore. This represent the decline of -128% The ebitda of Welcure Drugs & Pharmaceuticals Ltd for the Jun '26 is ₹ 0 crore as compare to the Mar '26 ebitda of ₹ -49.86 crore. This represent the decline of -100% The net profit of Starsource Multitrade Ltd changed from ₹ 0.25 crore to ₹ 0.02 crore over 9 quarters. This represents a CAGR of -67.45% The net profit of Welcure Drugs & Pharmaceuticals Ltd changed from ₹ -0.34 crore to ₹ 0 crore over 9 quarters. This represents a CAGR of -100.00% The Dividend Payout of Starsource Multitrade Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 yearsThe Dividend Payout of Welcure Drugs & Pharmaceuticals Ltd changed from 0 % on March 2021 to 0 % on March 2026 . This represents a CAGR of 0.0% over 6 years .

About Starsource Multitrade Ltd

Starsource Multitrade Limited was initially established on August 17, 1942 under the name 'Chemo Pharma Laboratories Limited'.
Name of the Company is given a change in name with due approval from Registrar of Companies effected on August 12, 2025.
Initially, the Company had been making Pharmaceuticals and also diversified into bulk drugs. However due to increase in competition and flow of new drugs, the Company had to dispose the business and pay all its liabilities and dues.
Presently the Company has its own cash resource, with this the Company is proposing to diversify and to take over Sick Company which has excellent future potential.
The Company is in advance in the negotiation to some other company and soon rehab to acquire business in Power and Chemicals. The existing Main Objects of Clause III (A) be altered by replacing the same with the following new Clause to carry on the business of buying, selling, reselling, importing, exporting, transporting, storing, promoting, marketing or supplying, trading, dealing in any manner whatsoever in all type of goods and commodities on retail as well as on wholesale basis in India or elsewhere during the year 2025.

About Welcure Drugs & Pharmaceuticals Ltd

Incorporated on 4th June, 1992, Welcure Drugs And Pharmaceuticals Limited(WDPL) was promoted by D C Jain, Sanjeev Jain and Sandeep Jain.
The promoters have interests in other companies such as Paam Pharmaceuticals, Pioneer Products, Alirox Abrasives, A K Laboratories, etc. WDPL had come out with a Rs 4-cr public issue in Aug.'94 to part-finance the Rs 12 Crore project to manufacture bulk drugs in Rajasthan and finance investments in a subsidiary, A K Laboratories (AKL).
The company has also submitted the letter of offer for a Rs 7.09-cr rights issue of equity shares in Jan.'96 to finance its expansion programmes. Products of WDPL include bulk drugs such as ampicillin and trimethoprim, drugs intermediates and pharmaceutical formulations.
It has decided to add amoxycillin and cloxacillin to its range with provision to manufacture ibuprofen.

FAQs for the comparison of Starsource Multitrade Ltd and Welcure Drugs & Pharmaceuticals Ltd

Which company has a larger market capitalization, Starsource Multitrade Ltd or Welcure Drugs & Pharmaceuticals Ltd?

Market cap of Starsource Multitrade Ltd is 15 Cr while Market cap of Welcure Drugs & Pharmaceuticals Ltd is 22 Cr

What are the key factors driving the stock performance of Starsource Multitrade Ltd and Welcure Drugs & Pharmaceuticals Ltd?

The stock performance of Starsource Multitrade Ltd and Welcure Drugs & Pharmaceuticals Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Starsource Multitrade Ltd and Welcure Drugs & Pharmaceuticals Ltd?

As of October 26, 2026, the Starsource Multitrade Ltd stock price is INR ₹105.66. On the other hand, Welcure Drugs & Pharmaceuticals Ltd stock price is INR ₹0.18.

How do dividend payouts of Starsource Multitrade Ltd and Welcure Drugs & Pharmaceuticals Ltd compare?

To compare the dividend payouts of Starsource Multitrade Ltd and Welcure Drugs & Pharmaceuticals Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.